Inovio Pharmaceuticals, Inc.
INO · Nasdaq · United States
Share price · INO
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when INO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 2 Nov 2026+213.7%
- 30 Oct 2026-21.9%
- 29 Oct 2026-16.9%
Nothing announced by INO that day or the session before.
- 21 Oct 2026-21.3%
- 14 Aug 2026+21.1%
Nothing announced by INO that day or the session before.
- 13 Aug 2026+16.9%
- 30 Jul 2026-36.9%
- 1 Jul 2026+8.2%
Nothing announced by INO that day or the session before.
- 7 May 2026+10.5%
Nothing announced by INO that day or the session before.
- 2 Apr 2026-35.1%
Share of unusual movement by asset
For each asset, the share of INO's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
INO-3107(Voceryq) | Approved | HPV-6 and HPV-11 antigensGene therapy / editing | Recurrent Respiratory Papillomatosis |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0.3M | $11M | $47M+ $1.4M short-term inv. | $49M-$15M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $11M | $32M+ $5.2M short-term inv. | $6.0M-$18M operating cash flow | report ↗ |
| 2026-Q1 | $0 | $14M | $26M+ $11M short-term inv. | $20M-$22M operating cash flow | report ↗ |
| 2025-Q3 | $0 | $13M | $37M+ $14M short-term inv. | $46M-$22M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $15M | $24M+ $23M short-term inv. | $24M-$21M operating cash flow | report ↗ |
| 2025-Q1 | $0.1M | $16M | $40M+ $28M short-term inv. | $20M-$27M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $19M | $22M+ $63M short-term inv. | $25M-$27M operating cash flow | report ↗ |
| 2024-Q2 | $0.1M | $23M | $34M+ $76M short-term inv. | $32M-$28M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $21M | $20M+ $86M short-term inv. | $30M-$29M operating cash flow | report ↗ |
| 2023-Q3 | $0.4M | $16M | $19M+ $149M short-term inv. | $34M-$29M operating cash flow | report ↗ |
| 2023-Q2 | $0.2M | $24M | $53M+ $142M short-term inv. | $36M-$32M operating cash flow | report ↗ |
| 2023-Q1 | $0.1M | $30M | $28M+ $196M short-term inv. | $41M-$37M operating cash flow | report ↗ |
| 2022-Q3 | $9.2M | $33M | $22M+ $260M short-term inv. | $38M-$67M operating cash flow | report ↗ |
| 2022-Q2 | $0.8M | $56M | $41M+ $307M short-term inv. | $109M-$51M operating cash flow | report ↗ |
| 2022-Q1 | $0.2M | $56M | $59M+ $301M short-term inv. | $79M-$62M operating cash flow | report ↗ |
| 2021-Q3 | $0.3M | $47M | $68M+ $327M short-term inv. | $60M-$46M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0.1M | $54M | $44M+ $14M short-term inv. | $21M-$89M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0.2M | $76M | $66M+ $28M short-term inv. | $27M-$104M operating cash flow | report ↗ |
| 2023-FY | $0.8M | $87M | $14M+ $131M short-term inv. | $34M-$124M operating cash flow | report ↗ |
| 2022-FY | $10M | $188M | $46M+ $207M short-term inv. | $70M-$216M operating cash flow | report ↗ |
| 2021-FY | $1.8M | $249M | $71M+ $330M short-term inv. | $76M-$216M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-05-20 | Shea Jacqueline Elizabeth · director, Chief Executive Officer | Option exercise | 28,296 | — | — | Form 4 |
| 2026-05-20 | KIES PETER · CFO | Option exercise | 8,700 | — | — | Form 4 |
| 2026-05-20 | Sumner Michael John · Chief Medical Officer | Option exercise | 9,450 | — | — | Form 4 |
| 2026-05-20 | Humeau Laurent · Chief Scientific Officer | Option exercise | 6,027 | — | — | Form 4 |
| 2026-05-20 | BENITO SIMON X · director | Award / grant (derivative) | 41,800 | — | — | Form 4 |
| 2026-05-20 | DANSEY ROGER D · director | Award / grant (derivative) | 41,800 | — | — | Form 4 |
| 2026-05-20 | Zoth Lota S. · director | Award / grant (derivative) | 41,800 | — | — | Form 4 |
| 2026-05-20 | Weiner David B. · director | Award / grant (derivative) | 41,800 | — | — | Form 4 |